Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegcetacoplan
- Development stage
- Approved
- Lead developer
- Apellis Pharmaceuticals
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravitreal
01
Overview
Pegcetacoplan is a pegylated peptide complement inhibitor that selectively binds to complement component 3 (C3) and its activation fragment C3b, thereby inhibiting the cleavage of C3 into C3a and C3b. This action blocks all three complement activation pathways (classical, alternative, and lectin), preventing downstream effects such as opsonization, inflammation, and formation of the membrane attack complex (MAC). Pegcetacoplan is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults via subcutaneous infusion and for geographic atrophy secondary to age-related macular degeneration via intravitreal injection. It was developed to address both intravascular hemolysis mediated by MAC formation and extravascular hemolysis mediated by C3b opsonization in PNH patients. Pegcetacoplan is considered first-in-class as a proximal complement inhibitor targeting C3.
- Brand names
- EmpaveliSyfovre
- Other names
- pegcetacoplan
02
Targets
C3C3b (Complement Component 3b)
Beyond the preview
Go deeper on pegcetacoplan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegcetacoplan.